AtriCure, Inc. (ATRC) director sells 3,564 shares at $38.80

Rhea-AI Filing Summary

AtriCure, Inc. director Karen Prange reported a sale of 3,564 shares of Common Stock on 2026-08-05 at $38.80 per share in a sale in open market or private transaction. Following this transaction, she directly holds 22,809 AtriCure shares.

Insider Trade Summary

Net Seller: 3,564 shares

Net Sell 1 txn

Insider Prange Karen

Role Director

Sold 3,564 shs ($138K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,564	$38.80	$138K

Holdings After Transaction: Common Stock — 22,809 shares (Direct)

Key Figures

Shares sold: 3,564 shares Sale price per share: $38.80 Shares held after transaction: 22,809 shares

3 metrics

Shares sold 3,564 shares Common Stock sold by director Karen Prange on 2026-08-05

Sale price per share $38.80 Per-share price for the 3,564 shares of Common Stock sold

Shares held after transaction 22,809 shares Directly held AtriCure Common Stock following the reported sale

Key Terms

Common Stock, Sale in open market or private transaction, acquired_disposed_code

3 terms

Common Stock financial

"security_title is listed as Common Stock for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Sale in open market or private transaction financial

"transaction_code_description notes a Sale in open market or private transaction"

acquired_disposed_code regulatory

"acquired_disposed_code is D, indicating a disposition of shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 09:19 AM Accepted by SEC EDGAR 08/07/2026 - 09:18 AM Learn about SEC filing dates

FAQ

What insider transaction did AtriCure (ATRC) report for Karen Prange?

AtriCure reported that director Karen Prange sold 3,564 common shares. The sale occurred on 2026-08-05 at a price of $38.80 per share, and was reported as a sale in open market or private transaction, leaving her with 22,809 shares held directly.

How many AtriCure (ATRC) shares did director Karen Prange sell?

Karen Prange sold 3,564 AtriCure common shares. The transaction was reported as a non-derivative sale of Common Stock, with the shares sold at $38.80 per share on 2026-08-05 in an open market or private transaction.

At what price were AtriCure (ATRC) shares sold in this Form 4?

The reported sale price was $38.80 per share. Director Karen Prange sold 3,564 shares of AtriCure Common Stock at this per-share price on 2026-08-05 in a transaction described as a sale in open market or private transaction.

How many AtriCure (ATRC) shares does Karen Prange hold after the sale?

After the reported sale, Karen Prange holds 22,809 shares. These holdings are reported as directly owned Common Stock following the 3,564-share sale disclosed for the transaction date 2026-08-05.

Does this AtriCure (ATRC) Form 4 include any derivative transactions?

No derivative securities are reported in this Form 4 data. The filing reflects a single non-derivative transaction in Common Stock, with no listed options, warrants, or other derivative instruments in the transaction or derivative summaries.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prange Karen

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2026		S		3,564	D	$38.8	22,809	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Karen N. Prange	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)